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Abstract
Background: Diagnosis of leptospirosis by the microscopic agglutination test (MAT) or by culture is confined to specialized
laboratories. Although ELISA techniques are more common, they still require laboratory facilities. Rapid Diagnostic Tests
(RDTs) can be used for easy point-of-care diagnosis. This study aims to evaluate the diagnostic performance of the RDTs
LeptoTek Dri Dot, LeptoTek Lateral Flow, and Leptocheck-WB, prospectively.
Methodology: During 2001 to 2012, one or two of the RDTs at the same time have been applied prior to routine diagnostics
(MAT, ELISA and culture) on serum specimens from participants sent in for leptospirosis diagnosis. The case definition was
based on MAT, ELISA and culture results. Participants not fulfilling the case definition were considered not to have
leptospirosis. The diagnostic accuracy was determined based on the 1st submitted sample and paired samples, either in an
overall analysis or stratified according to days post onset of illness.
Results: The overall sensitivity and specificity for the LeptoTek Dri Dot was 75% respectively 96%, for the LeptoTek Lateral
Flow 78% respectively 95%, and for the Leptocheck-WB 78% respectively 98%. Based on the 1st submitted sample the
sensitivity was low (51% for LeptoTek Dri Dot, 69% for LeptoTek Lateral Flow, and 55% for Leptocheck-WB), but substantially
increased when the results of paired samples were combined, although accompanied by a lower specificity (82%
respectively 91% for LeptoTek Dri Dot, 86% respectively 84% for LeptoTek Lateral Flow, and 80% respectively 93% for
Leptocheck-WB).
Conclusions: All three tests present antibody tests contributing to the diagnosis of leptospirosis, thus supporting clinical
suspicion and contributing to awareness. Since the overall sensitivity of the tested RDTs did not exceed 80%, one should be
cautious to rely only on an RDT result, and confirmation by reference tests is strongly recommended.
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Introduction
Leptospirosis is caused by microorganisms of the genus Leptospira.
It is one of the world’s most wide-spread zoonoses, with a mean
global incidence of endemic and epidemic leptospirosis of 5 per
100,000 and 14 per 100,000 population, respectively [1]. It causes
an acute febrile illness [2] with a wide diversity of milder clinical
signs such as headache, malaise, myalgia, conjunctival suffusion and
sometimes a transient rash. However, the illness can rapidly develop
into a severe, potentially fatal form with a high mortality rate [3].
Leptospirosis is often overlooked since it mimics many other
diseases, including dengue, malaria, influenza and hantavirus
infections [4], making differential diagnosis very difficult based on
clinical grounds alone. Laboratory tests are therefore the basis of a
confirmed case of leptospirosis.
The most commonly used laboratory tests are based on
detection of antibodies against the leptospires. Pathogenic
leptospires enter the body through small cuts or abrasions, or
via mucous membranes and possibly through wet skin. After
infection, leptospires circulate in the blood stream, with a
bacteremic phase lasting for up to 10 days post onset of the
disease (DPO). Detectable antibodies appear in the blood about 5–
10 DPO [5], and sometimes later, especially if antibiotic treatment
is instituted [4]. These antibodies can be detected by a variety of
laboratory assays such as the microscopic agglutination test
(MAT), enzyme-linked immunosorbent assay (ELISA) and indirect
fluorescent antibody test (IFAT) [6]. Currently, the MAT is
considered the reference standard in serodiagnosis and as such has
a worldwide application. However, MAT and ELISA are
technically demanding and relatively expensive tests and therefore
not widely applicable in peripheral healthcare facilities, especially
in tropical and subtropical developing regions where leptospirosis
is most endemic. Culturing leptospires out of blood provides proof
of infection but is insensitive [7] and has little clinical value for
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patient management as it can take weeks to months to confirm
results. PCR on blood has proven to be useful in the first week of
the disease [8], however many laboratories are not equipped to
run PCR tests. Hence, for most clinical situations rapid diagnostic
tests (RDTs) can play an important role in immediate case
detection and clinical management. Most commonly used RDTs
are based on the immunochromatographic lateral flow technology.
To date, a variety of RDTs have been described and evaluated
in various papers [9–11], most of these being short term
retrospective evaluations and often concern evaluations of a single
RDT. Our aim was to evaluate the diagnostic accuracy of three
RDTs, applied on serum specimens from suspected leptospirosis
patients from The Netherlands in a prospective cohort of
leptospirosis suspected patients. Additional aims were to assess
whether there are differences between the three tests and whether
using the tests at different times since patient’s onset of symptoms
leads to differences in diagnostic accuracy. The RDTs used in this
research were available in the Netherlands, or could be easily
imported.
Materials and Methods
Standards for the Reporting of Diagnostic accuracy testing
(STARD) checklist were adhered to throughout the text (Table S1)
[12].
Study participants
The Royal Tropical Institute (KIT), Biomedical Research
houses the WHO/FAO/OIE and National Collaborating Centre
for Reference and Research on Leptospirosis (NRL), which
confirms about 99% of the suspected cases of leptospirosis in
The Netherlands. The typical annual number of suspected cases is
around 500, of which approximately 30 are confirmed leptospi-
rosis cases. About 50% of the confirmed cases have contracted
leptospirosis during travel abroad. In the period of evaluation, July
2001 to August 2012, the population in The Netherlands was
stable at about 16 million. During this period, all human blood
specimens sent by physicians practicing in the Netherlands to
NRL for leptospirosis diagnosis were tested upon arrival by routine
diagnostics. In most cases only one sample was received per
participant, in other cases two or more samples. Further inclusion
and exclusion criteria of samples and participants are depicted in a
flow diagram (Figure 1). Laboratory tests routinely performed are
MAT and in-house IgM-ELISA. Culture was done as described
below. A single or a combination of two RDTs were prospectively
performed for evaluation purposes.
Leptospirosis case definition
Patients were considered as having leptospirosis based on one or
more of the following criteria: (i) single MAT titer with a
pathogenic strain $1:160, (ii) single IgM-ELISA titer $1:160, (iii)
positive culture or (iv) seroconversion/$four-fold titer rise MAT
or IgM ELISA (titer #1:20 to $1:80) in paired samples taken at
least 2 days apart [13]. The treating physician was encouraged to
send multiple samples for laboratory testing for all participants.
Laboratory methods
RDTs were applied prior to and independent of routine
diagnostic testing. All tests were performed by skilled staff of NRL
(10 persons) who followed detailed protocols about interpretation
of tests. NRL is accredited based on ISO 15189 since 2006. All
serological tests were performed on serum specimens which were
inactivated in a 56uC water bath for 30 minutes before testing.
Culture. Culture was initiated for blood, plasma or serum
samples collected within the first 10 days of disease. Urine was
cultured at all time points during the course of disease within
2 hours after voiding. Fletcher medium and Ellinghausen-
McCullough as modified by Johnson and Harris (EMJH) culture
medium was used [14]. EMJH was supplemented with 5-
fluorouracil (200 mg/ml), 1% (V/V) rabbit serum and 1% (V/V)
fetal calf serum or combinations [15]. Inoculated media were
incubated for a maximum of 4 months at 30uC and (bi)weekly
checked for leptospiral growth by darkfield microscopy.
Microscopic agglutination test. The MAT was performed
with a panel of live leptospires as described elsewhere [15]. The
panel consisted of 16 strains of the pathogenic serovars Bratislava,
Ballum, Canicola, Grippotyphosa, Hebdomadis, Icterohaemor-
rhagiae, Copenhageni, Poi, Pomona, Proechimys, Hardjo, Sax-
koebing and Sejroe, and the non-pathogenic serovar Patoc. Sera
from patients who visited a country outside the Netherlands within
one month prior to the day of onset of symptoms were also tested
with an additional panel of 12 globally representative strains, i.e.
the pathogenic serovars Australis, Rachmati, Bataviae, Celledoni,
Cynopteri, Mini, Panama, Pyrogenes, Shermani and Tarassovi,
and the non-pathogenic serovars Andamana and Semaranga.
IgM ELISA. In-house developed ELISA for the detection of
Leptospira-specific IgM antibodies (IgM ELISA) was performed
with antigen prepared from the local strain Wijnberg (serovar
Copenhageni, serogroup Icterohaemorrhagiae) [16,17].
Rapid diagnostic tests. Three rapid diagnostic serological
tests were used according to their availability: (i) 2001–2008
LeptoTek Dri Dot, Organon Teknika B.V., later bioMe´rieux B.V.,
Boxtel, the Netherlands. (ii) 2001–2004 LeptoTek Lateral Flow,
Organon Teknika B.V. Boxtel, the Netherlands. (iii) 2004–2012
Leptocheck-WB, Zephyr Biomedicals, Verna Goa, India. Lepto-
Tek Lateral Flow and Leptocheck-WB are lateral flow immuno-
chromatographic tests. These are both qualitative, sandwich
immunoassays intended for the detection of Leptospira-specific
IgM antibodies in humans. The test can be read after 10 to
15 minutes and can be used for serum/plasma or whole blood
Author Summary
Leptospirosis is one of the world’s most spread zoonoses
causing acute fever. The illness can rapidly develop into a
severe, potentially fatal, form with a high mortality rate.
Laboratory tests are needed to confirm the diagnosis.
Culturing leptospires from patient material can take
months to grow. Therefore, most used laboratory tests
are based on detection of antibodies against leptospires.
The microscopic agglutination test is considered the
reference standard but is only performed at specialized
laboratories. In this study, we measured the diagnostic
accuracy of three rapid diagnostic tests (RDTs) by doing a
prospective evaluation during 11 years. These tests
produce results within 15 minutes. The overall sensitivities
(77%) and specificities (96%) were similar for the RDTs.
Evaluating the first submitted specimen resulted in lower
sensitivities (51% for LeptoTek Dri Dot, 69% for LeptoTek
Lateral Flow, and 55% for Leptocheck-WB). When paired
specimens were evaluated, the sensitivity increased
although the specificity decreased (82% respectively 91%
for LeptoTek Dri Dot, 86% respectively 84% for LeptoTek
Lateral Flow, and 80% respectively 93% for Leptocheck-
WB). Based on these results confirmation by reference tests
is still strongly recommended, although the RDTs contrib-
ute to the diagnosis of leptospirosis, thus supporting
clinical suspicion and contributing to awareness.
Rapid Tests Evaluation for Human Leptospirosis
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specimens. LeptoTek Dri Dot is a latex agglutination assay and
detects Leptospira-specific antibodies (IgM and IgG) in human sera.
The rapid tests were performed according to the manufacturer’s
instructions. For the LeptoTek Lateral Flow 5 ml serum was
spotted in the sample port of the device, running buffer was added
and the test was read after 10 minutes. For the Leptocheck-WB
10 ml serum was spotted in the sample port of the device and
15 minutes after running buffer was added the test was read. Both
tests were valid when the control band stained. Valid tests were
scored positive when a test band was observed, negative when no
band was observed and indeterminate when it was unclear
whether a band was observed or not. Invalid tests were repeated.
For the LeptoTek Dri Dot 10 ml of serum was mixed with the
dried leptospiral-antigen-coated latex spot on the agglutination
card. The test was read within 30 seconds and scored positive
when agglutination was observed, negative when there was no
agglutination and indeterminate when occurrence of agglutination
was unclear.
Data analyses
Data were entered into a Laboratory Information System
(LASSIST, Mechatronics Software Applications BV, the Nether-
lands) and exported and analyzed in SPSS (version 19, IBM, NY,
USA). These included patient data obtained from the request form
(i.e. gender, date of birth, date of onset, travel history). The results
of each diagnostic test of every sample were entered into the
database. Follow-up samples taken less than two days after the first
sample were excluded. Indeterminate results were regarded as
negative, unless otherwise stated.
Overall accuracy. In this analysis, the overall accuracy of
RDTs for diagnosing leptospirosis for any submitted sample was
estimated. Diagnostic accuracy was defined by sensitivity and
specificity with 95% confidence intervals (CIs) [18]. For these
analyses, participants were considered positive if they had a
positive RDT result in at least one of the submitted samples
(participant-level, not on individual samples received). Sensitivity
was calculated in participants who fulfilled the case-definition,
specificity on those who did not. The three RDTs were considered
different from each other if the 95% confidence intervals did not
overlap.
Overall accuracy – First sample sent in and follow-up
sample. To avoid potential overestimations of sensitivity and
underestimations of specificity of the individual test in the above
analyses, a subgroup analysis was completed on only the first
sample that was sent in, and, if available, on the follow-up sample
(paired samples), if taken within 1 month. This reflects clinical
practice better than the previous analysis, as it represents the
disease period when leptospirosis diagnostics are typically
requested by the clinician. As well, this analysis does not depend
on a defined first day of illness. The three tests were considered
different from each other if the 95% confidence intervals did not
overlap.
Time trends. For those patients with data available on their
first day of illness (50%), the diagnostic accuracy of the serologic
Figure 1. Flow chart of participants and rapid diagnostic tests.
doi:10.1371/journal.pntd.0002290.g001
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tests was calculated at different time-periods, i.e., 0–4 days post
onset of symptoms (DPO) (early acute), 5–10 DPO (late acute), 11–
20 DPO (convalescent) and .20 DPO (late convalescent). If
multiple samples of a participant were taken in the same time-
period, the sample with the lowest DPO was included.
Sensitivity analyses. A substantial proportion of the samples
were scored indeterminate in the RDTs. To assess the impact of
the interpretation of indeterminate results as considered negative
in the previous analyses, a sensitivity analysis of the diagnostic
accuracy was conducted by allocating the indeterminate scores to
either the negative test results or positive test results or by
excluding these indeterminate scores for 1st and follow-up samples.
Furthermore the predictive value of an indeterminate versus a
negative test result was assessed: from participants whose first test
result was either indeterminate or negative, we looked at the RDT
result in the follow-up sample to calculate the proportion of
participants fulfilling the case definition. This denotes the
proportion of patients changing from a negative or indeterminate
RDT to a positive RDT.
An additional analysis was completed to determine the potential
differences in diagnostic accuracy of the RDTs between infecting
serogroups. This analysis considered infections with serogroup
Icterohaemorrhagiae, Grippotyphosa, other serogroups and not
classifiable serogroups for the 1st sample and paired samples when
available.
To investigate the consistency of the diagnostic accuracy of
these RDTs through the periods of use, sensitivity and specificity
were compared for each diagnostic test for the 1st sample and
paired samples by years the test was completed.
Ethical statement
This data collection was exempted from ethical review of
human subjects research by the Medical Ethical Review Com-
mittee of the Academic Medical Centre, University of Amsterdam
(W12_076#12.17.0092). All data presented have been de-
identified and were not attributable to individual patients.
Results
During the 11 years of data collection, blood specimens from
5393 participants suspected of leptospirosis were submitted to
NRL for testing. The majority of participants (95.4%) were tested
by MAT, IgM ELISA and one or more of the rapid tests (Figure 1);
however there were short periods where no RDT could be
performed due to their unavailability on the international market
(Table S2). No RDT could be completed for 234 participants.
Furthermore, 15 participants were excluded as there was no MAT
or ELISA completed, as a prerequisite of the reference standard
and case definition, leaving a total of 5144 patients. Follow-up
specimens were received from 929/5144 participants and 53.1%
of the participants had a documented DPO.
There were 367 (6.7%) leptospirosis cases fulfilling the case
definition, with a male to female sex ratio of about 6:1. The sex
ratio of non-leptospirosis cases was 2:1. The mean age of cases and
non-cases was 39.7 and 42.1 years, respectively. Male leptospirosis
cases were older (mean age 40.2, SD 15.7) than female cases (mean
age 36.8, SD 17.3). Table 1 presents an overview of characteristics
of the eligible study participants. Table 2 presents an overview of
the participants fulfilling the case definition. There were no invalid
test results reported for the RDTs, i.e. the control band in the
LeptoTek Lateral Flow and Leptocheck-WB stained in all tests
performed.
RDTs were performed on 1st and follow-up specimens from
861/929 participants (16.7% of all participants); 80.7% of the
leptospirosis cases, and 11.8% of the non-leptospirosis participants.
The total median number of days between 1st and follow-up
sample was 16 days (IQR 11 to 28). For the confirmed
leptospirosis participants this was 14 days (IQR 8 to 22), versus
20 days (IQR 3 to 200) for the non-leptospirosis participants
(P,0.05, Kruskal-Wallis test).
Overall accuracy
The overall sensitivity and specificity, calculated on all samples
from early acute till the late convalescent phase showed a
sensitivity of 75% (95% CI 69% to 79%) for LeptoTek Dri Dot,
78% (95% CI 69% to 85%) for LeptoTek Lateral Flow and 78%
(95% CI 71% to 83%) for Leptocheck-WB. The specificity was
96% (95% CI 95% to 97%) for LeptoTek Dri Dot, 95% (95% CI
94% to 96%) for LeptoTek Lateral Flow and 98% (95% CI 97%
to 98%) for Leptocheck-WB (Table 3). There were no marked
differences between the three tests; the sensitivities and specificities
were similar with overlapping confidence intervals.
Accuracy of first sample and follow-up sample
When considering only the first sample that was sent in for each
patient, the sensitivity of each test dropped dramatically from 75%
to 51% and from 78% to 55% for the LeptoTek Dri Dot and the
Leptocheck-WB, respectively. The sensitivity of the LeptoTek
Lateral Flow decreased from 78% to 69%, although not a
statistically significant change. The specificity of all tests remained
more or less the same. Test results from paired samples (either one
of the samples positive) increased the sensitivity significantly from
51% to 82% for the LeptoTek Dri Dot and from 55% to 80% for
the Leptocheck-WB. The increase from 69% to 86% for the
LeptoTek Lateral Flow was not statistically significant. The
corresponding decrease in specificity was significant, i.e. from
96% to 91% for the LeptoTek Dri Dot, from 96% to 84% for the
LeptoTek Lateral Flow and from 98 to 93% for the Leptocheck-
WB (Table 3).
Time trends
For 2733 participants (53.1% of study participants) the first day
of onset of symptoms was known. All three tests show a lower
sensitivity during the early acute phase of the disease (till DPO 4),
which increased during DPO 5–10 and DPO 11–20, while the
specificity of all tests remained relatively stable (Table 4).
LeptoTek Lateral Flow was performing the best at DPO 0–4
(sensitivity of 62%, 95% CI 41% to 79% and specificity of 98%, 95
CI 93% to 99%).
Sensitivity analyses
The proportion of the indeterminate results for the 1st sample
for LeptoTek Dri Dot were 10/256 (4%) in the participants
fulfilling the case definition and 85/2903 (3%) in the participants
not fulfilling the case definition. For the LeptoTek Lateral Flow,
these proportions were 4/108 (4%), respectively 173/1292 (13%),
and for the Leptocheck- WB 17/183 (9%), respectively 239/2551
(9%).
Allocation of indeterminate results to positive scores did not
substantially change sensitivity, but it did have an impact on
specificity (Figure 2). For the LeptoTek Dri Dot, the specificity
decreased from 96% to 93% for the 1st submitted sample and from
91% to 81% for the paired samples. The LeptoTek Lateral Flow
showed a decrease of the specificity from 96% to 82% for the 1st
sample and 84% to 62% for the paired samples, while the
Leptocheck-WB showed a decrease from 98% to 88% and from
93% to 80% respectively.
Rapid Tests Evaluation for Human Leptospirosis
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About 28% of the participants with an initial indeterminate
result for the LeptoTek Dri Dot and Leptocheck-WB were later
confirmed with leptospirosis in follow-up testing, and had a
positive RDT compared to only 10% of participants with an initial
negative result. For the LeptoTek Lateral Flow, the numbers are
somewhat different with 9% positive results after the first sample
was indeterminate, and 4% positive results after the first sample
was negative, but the same trend is present (Table S4).
Exclusion of indeterminate results showed an increasing
sensitivity and decreasing specificity for all RDTs and for all time
points, though not statistically significant. When stratifying the
samples according to the defined time-periods of the disease, the
same trend was observed (Table S3).
The sensitivity of RDTs appeared to depend on the infecting
serogroup (Table S3). In general infecting serogroup Icterohae-
morrhagiae yielded a higher sensitivity for all three RDTs
compared to the other categories of serogroups. Differences were
significant in the following cases: The LeptoTek Dri Dot showed
a higher sensitivity for the paired samples in the Icterohaemor-
rhagiae infections (98%) compared to the other infections (81%)
and non-classifiable serogroup infections (60%). The 1st submit-
ted samples of the latter category also had a lower sensitivity
(38%) compared to the Icterohaemorrhagiae group infections
(67%).
The LeptoTek Lateral Flow showed a higher sensitivity in both
the 1st submitted samples and the paired samples for the
Icterohaemorrhagiae infections (85% respectively 100%) com-
pared to for ‘non-classifiable serogroups’ (51% respectively 63%).
Leptocheck-WB showed a higher sensitivity in the 1st samples
(68%) as well as the paired samples (95%) for the Icterohaemor-
rhagiae infections compared to the category ‘non-classifiable
serogroups’ (1st submitted sample 38%, paired samples 65%).
Temporal consistency
To investigate the consistency of the diagnostic accuracy of
these RDTs over the time period 2001 to 2011, the diagnostic
accuracy based on the 1st submitted sample and paired samples for
each year for each test was compared (Figure 3). Significant
variation was observed in the following cases: for the 1st sample
submitted, the sensitivity of the LeptoTek Dri Dot decreased from
77% in 2001 to 37% in 2005 combined with increasing specificity
from 93% to 98%. During the same years the paired samples
showed a decrease in sensitivity from 100% to 67%. Also the
LeptoTek Lateral Flow showed on the 1st submitted sample a
decreasing sensitivity from 100% in 2001 to 50% in 2003, whereas
the specificity increased from 87% to 99%. For the paired samples,
the specificity increased from 60% to 100%. On the contrary,
based on the 1st submitted sample the Leptocheck-WB showed an
increase in sensitivity, from 36% in 2005 to 78% in 2009,
combined with a decreasing specificity from 100% to 97%.
Discussion
This paper presents data of a prospective evaluation of three
RDTs for leptospirosis, the LeptoTek Dri Dot, the LeptoTek
Lateral Flow and the Leptocheck-WB, on a well-defined Dutch
Table 1. Characteristics of participants.
Characteristic Total Leptospirosis patients Non leptospirosis patients
(n=5144) (n =367) (n=4777)
Male{ - no. (%) 3496 (67.9) 314 (85.6) 3181 (66.6)
Mean age* - years (SD) 41.9 (18.3) 39.7 (15.9) 42.1 (18.5)
Mean age males - years (SD) 42.9 (18.0) 40.2 (15.7) 43.2 (18.2)
Mean age females - years (SD) 39.6 (18.8) 36.8 (17.3) 39.7 (18.9)
Travel history no. (%) 1392 (27) 179 (48.8) 1213 (25.4)
Europe 268 36 232
Asia 531 108 423
Africa 198 5 193
South America 153 11 142
Central and North America 102 16 86
Middle East 58 2 56
Australia 12 0 12
Unknown 70 1 69
DPO known - no. (%) 2733 (53.1) 338 (92.1) 2395 (50.1)
Single serology sample - no. (%) 4215 (81.9) 48 (13.1) 4167 (87.2)
Multiple serology samples - no. (%) 929 (18.1) 319 (86.9) 610 (12.8)
DPO 1st serology sample# – median (IQR) 10 (5–22) 7 (5–11) 10 (5–24)
DPO follow up serology sample## – median (IQR) 24 (16–39) 21 (14–30) 28 (17–44)
Culture - no. (%) 1455 (28.3) 223 (60.8) 1232 (25.8)
{gender was registered for 5139 participants: 367 leptospirosis patients; 4772 non leptospirosis patients.
*Age was registered for 5143 participants: 367 leptospirosis patients; 4776 non leptospirosis patients.
#DPO of first sample was calculated from 2703 participants of whom first day of onset was known as well as date of sample collection: 330 leptospirosis patients; 2373
non leptospirosis patients.
##DPO of follow up sample was calculated from 630 participants of whom first day of onset was known as well as date of sample collection: 276 leptospirosis patients;
354 not leptospirosis patients.
doi:10.1371/journal.pntd.0002290.t001
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population. The overall sensitivity and specificity did not vary
much between the tests, with sensitivity ranging from 75% to 78%
and specificity ranging from 95 to 98%.
However, when based on first submitted sample only, the
sensitivity of all tests depreciated substantially, with corre-
sponding specificities remaining high. The sensitivity of the
LeptoTek Dri Dot and the Leptocheck-WB was markedly
lower, i.e. 51% and 55%, respectively while the sensitivity of
the LeptoTek Lateral Flow test dropped less to a still
appreciable 69%. This low sensitivity of first sample can be
explained by the fact that these samples usually are collected at
an early stage of disease when antibodies are not present yet at
detectable levels [15]. Consistently, the sensitivity of the three
tests increased to more than 80% when results of a follow-up
sample were included, supporting a significant increase of sero-
diagnostic sensitivity when using paired samples as previously
reported [10,15]. However, as the sensitivity increased with
paired samples, the concomitant specificity reduced, with the
Table 2. Diagnostic test and serogroup of Leptospirosis positive patients (n = 367).
Fullfillment of Case definition: Multiple positive features, n= 282 Single positive feature, n =85
Culture positive 31 6
MAT$1:160 253 20
IgM$1:160 234 45
Seroconversion MAT 140 4
Seroconversion IgM ELISA 108 10
Probable infecting serogroup* Autochthonous cases, n =188 Imported cases, n=179
Grippothyphosa 27 (14.4%) 15 (8.4%)














not classifiable 53 (28.2%) 74 (41.3%)
*Probable infecting serogroup is based on titers in MAT and typing results of positive cultures (Autumnalis n = 3, Bataviae n= 2, Canicola n = 2, Grippotyphosa n = 5,
Hebdomadis n = 1, Icterohaemorrhagiae n= 19, Javanica n = 2, Pyrogenes n = 2, Shermani n = 1). Probable infecting serogroup could not be determined if patient was a
case based only on IgM-ELISA or had several similar reacting serogroups in MAT.
doi:10.1371/journal.pntd.0002290.t002
Table 3. Overall case sensitivity and specificity of rapid diagnostic tests.
Assay Sensitivity % CI Specificity % CI
LeptoTek Dri Dot 1st sample 131/256 51 45–57 2795/2903 96 96–97
paired samples 137/167 82 76–87 261/286 91 87–94
Any sample 194/259 75 69–79 2795/2909 96 95–97
LeptoTek Lateral Flow 1st sample 74/108 69 59–77 1235/1292 96 94–97
paired samples 56/65 86 76–93 116/138 84 77–89
Any sample 85/109 78 69–85 1229/1295 95 94–96
Leptocheck-WB 1st sample 100/183 55 47–62 2495/2551 98 97–98
paired samples 103/129 80 72–86 162/174 93 88–96
Any sample 153/197 78 71–83 2497/2560 98 97–98
doi:10.1371/journal.pntd.0002290.t003
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largest reduction found for the LeptoTek Lateral Flow, i.e.
from 96% to 84%.
Clinically this indicates that with around 500 suspected cases
annually received at the NRL, comprising approximately 30
confirmed leptospirosis cases, RDTs used on the first sample
alone, would lead to between half (LeptoTek Dri Dot, sensitivity of
51%) and a third (LeptoTek Lateral Flow) of the cases being
missed. Yet, if paired samples are considered, then only 4 to 6
confirmed leptospirosis patients would be missed. This strongly
advocates for clinicians to provide follow-up samples [15]. These
paired samples, however, increase the number of false positives
(from 17 to 33–75), which might contribute to an unneeded
continuation of treatment with antibiotics.
It should be pointed out that in most situations, where
leptospirosis is highly endemic, availability of only one acute
phase sample is common practice and, hence, the diagnostic
accuracy of tests on early acute samples is most relevant. In
general, these RDTs showed disappointingly low sensitivities at the
early stage of the disease, although associated with acceptable
specificities of around 97%. From the subgroup analysis involving
samples with known DPO, the LeptoTek Lateral Flow Test
presents a favorable exception. Its sensitivity in the early acute
phase was 62%, which is significantly higher than the sensitivity of
the Leptocheck-WB (27%) and the LeptoTek Dri Dot (42%).
From the literature, 62% is also higher than usually reported on
the sensitivity of the MAT and ELISA in the earliest stage of the
disease [10,15,19]. Apparently, this test is more capable to
effectively detect ‘early’ antibodies and, hence, presents a
respectable adjunct laboratory tool enabling a timely start of
adequate care handling of patients.
This higher sensitivity in the early acute phase cannot be
explained by the choice of antigen, which is most likely similar,
since both lateral flow assays (LFAs) have been constructed using
crude antigen probably derived from Leptospira biflexa, serovar
Patoc, strain Patoc I [20]. However, differences in the diagnostic
accuracy between the two LFAs might be caused by differences in
the production, such as applying different amounts of antigen to
the LFAs or providing different quantities of conjugate. Of note,
visual inspection albeit subjective, judged the staining of the band
in the LeptoTek Lateral Flow test stronger than that of the
Leptocheck-WB (unpublished observation) facilitating an easier
positivity score. Differences found in the diagnostic accuracy of the
LeptoTek Dri Dot can easily be explained by the use of a different
antigen that consists of crude antigen derived from L. borgpetersenii,
serovar Hardjo type Bovis, strain Lely 607 [21], although
differences in production procedures might remain a valid
explanation.
All RDTs showed a lower specificity when testing paired
samples compared to the 1st submitted sample only. A possible
explanation is that cases from whom follow-up samples were
received more frequently present with persistent complaints due to
chronic disorders such as autoimmune diseases that are notorious
for causing cross-reactions in serological assays. However, be
aware that in general, the more tests one does, the more likely the
tests will be positive (which can lead to an increase in false
positives). In this study, we have seen that for all three RDTS as
sensitivity rises, specificity convergently decreases.
An unexpected high percentage of indeterminate results were
found, considering the fact that the reading of the RDTs was done
on a daily basis by a small group of well-experienced staff. This
indicates that these tests are not always easily read. Although we
found a high proportion of tests results to be indeterminate,
especially for the LeptoTek Lateral Flow, this does not imply that
such indeterminate results are of no value. In the sensitivity
analyses we saw that scoring all indeterminate results as positive
(instead of negative or excluded from analyses) resulted in an
increase in the sensitivity of a test, as expected, but this
corroborated with an unwanted reduction of test specificity,
depending on the proportion of indeterminate results. Therefore,
there may be practical consequences of a decision to score an
indeterminate result as positive or negative. In case of a first
sample giving an indeterminate result, a clinician might choose to
regard this result as a negative result and not send in a follow-up
sample. However, we have seen in those patients with follow-up
samples, that in about 28% of the cases where the first sample gave
an indeterminate LeptoTek Dri Dot or Leptocheck-WB result, the
follow up sample gave a positive result and likely is a true positive,
compared to only 10% of the first samples with a negative
outcome. Hence, this implies that the indeterminate results incline
more towards a final true case than negative results. Apart from
the fact that a follow-up sample always should be issued after
initial negative outcome, it is particularly advised to submit a
follow-up specimen in case of an indeterminate result.
From the additional diagnostic accuracy of the RDTs by
infecting serogroup, the sensitivity of all three RDTs was higher
for infection with the Icterohaemorrhagiae group compared to
infections with other serogroups. There is no conclusive explana-
tion why infections with the other categories are associated with
lower sensitivity. It may be that patients infected with Icterohae-
morrhagiae present with more severe disease and may elicit strong
humoral responses [22]. The finding that the test sensitivity
depends on the causative leptospires associated with that fact that
there is a wide diversity of geographic distribution of most
Leptospira serovars suggests that the diagnostic accuracy of the
various tests most likely will vary in different geographical
locations. This explains, at least in part, the discrepant results of
RDTs in previous studies performed in various regions [9,10] and
reiterates that it is imperative to do a local evaluation and
validation of tests prior to implementation.
The results revealed that the diagnostic accuracy of the RDTs
varies through the years of our study. The sensitivity of the
LeptoTek Lateral Flow and LeptoTek Dri Dot tended to decrease
during the years while the Leptocheck-WB increased in sensitivity.
Although it is unclear why this variability is present, it implies that
one cannot rely on a constant performance of commercial RDTs,
Table 4. Sensitivity and specificity of rapid diagnostic tests at
different days post onset (DPO).
Assay DPO Sensitivity % CI Specificity % CI
LeptoTek Dri Dot 0–4 27 17–40 97 94–98
5–10 55 47–63 96 94–98
11–20 83 74–89 96 93–98
.20 74 66–80 96 95–98
LeptoTek
Lateral Flow
0–4 62 41–79 98 93–99
5–10 75 62–84 94 89–96
11–20 81 69–90 93 88–96
.20 85 75–92 95 91–97
Leptocheck-WB 0–4 42 28–58 97 95–99
5–10 65 55–74 96 94–97
11–20 72 62–81 98 95–99
.20 70 61–78 97 95–98
doi:10.1371/journal.pntd.0002290.t004
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hence emphasizing the importance of continuous and thorough
quality control of the RDTs by the manufacturer. Moreover, for
the user this necessitates the evaluation of new purchases,
preferably by using a standardized set of sera comprising a range
of low to high ‘reactors’.
The validity of our data is positively affected by the prospective
nature of the evaluation as well as the use of fresh specimens.
Furthermore, all participants suspected for leptospirosis were
included in the study, allowing those who did not meet the case
definition to serve as controls, hence evading the use of a less
realistic, separate sample ‘healthy controls’ [23]. The case
definition in this study was based both on culture and serology
(MAT and IgM-ELISA). The MAT has a disappointing low
sensitivity in the early phase of infection [15,24] and consequently,
Figure 2. Sensitivity and specificity of the three RDTs of the 1st submitted sample and paired samples. Intermediate results are
considered either negative (neg) or positive (pos), or are excluded (ex). Panel A: sensitivity. Panel B: specificity.
doi:10.1371/journal.pntd.0002290.g002
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Figure 3. Sensitivity and specificity of the three RDTs of the 1st submitted sample and paired samples. Results are presented for each
year. Panel A: sensitivity. Panel B: specificity.
doi:10.1371/journal.pntd.0002290.g003
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reliance on only the MAT as reference standard would result in a
proportion of incorrect false positive scores for the RDTs with an
erroneous lower specificity. The RDTs were performed by well-
trained staff who were used to (optically) reading the tests results
and performed prior to serologic tests and culture.
The study also presents with limitations. Only a subgroup of
participants had their first day of illness documented and
documentation on both treatment and hospitalization was not
available. This information could have affected the test results,
since it is known that the use of antibiotics reduces the immune
response. Follow-up samples were not received from all partici-
pants. Therefore what is considered a false positive RDT result
could actually have turned out to be leptospirosis cases, if a
confirmatory sample had been received. With a high level of
indeterminate tests, the study misses information on repeatability
or reproducibility.
Conclusion and recommendations
The LeptoTeK Lateral Flow presents in all scenarios with the
best sensitivity and equally good specificity of all three RDT tests.
All three tests, LeptoTek Dri Dot, LeptoTek Lateral Flow and
Leptocheck-WB present useful antibody tests contributing to the
diagnosis of leptospirosis. For sure, confirmation of clinical
suspicion will contribute to increased local awareness of leptospi-
rosis. Confirmation might also be beneficial for the clinical
management of the patient. On the other hand, it should be noted
that, especially in the early phase, a negative RDT and a high
clinical suspicion still warrants antibiotic treatment since (untreat-
ed) leptospirosis is a potential fatal disease. Unfortunately,
currently LeptoTek Dri Dot and LeptoTek Lateral Flow are not
available due to manufacturer issues, presently leaving few options.
The overall sensitivity of the tested RDTs did not exceed 80%,
while their performance might depend on batch-to-batch and
year-to-year variations as well as on varying ecological niches
containing different circulating serovars. This latter drawback
might be extended with a reduced diagnostic accuracy due to past
leptospiral infections or infections with other causative agents in
high endemic areas, causing cross-reactions in these tests [9]. For
these reasons, one should be cautious to only rely on an RDT
result. Confirmation by reference tests is strongly recommended,
and further conclusive studies are needed in endemic regions.
From this study we have seen that rapid testing is not synonymous
with easy testing. Reading of tests by eye is subjective and depends
on the experience of the reader. At least it is of great importance
that a test result, in case of doubt, is reported as such, indicating
the need for a follow-up sample, especially evading the inclination
of the reader to score a doubtful signal as a positive score.
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